Usca Ria LLC Decreases Stake in Novartis AG (NYSE:NVS)

Usca Ria LLC decreased its position in Novartis AG (NYSE:NVS) by 12.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 67,485 shares of the company’s stock after selling 9,926 shares during the period. Usca Ria LLC’s holdings in Novartis were worth $6,390,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. TCI Wealth Advisors Inc. increased its stake in shares of Novartis by 18.3% during the 4th quarter. TCI Wealth Advisors Inc. now owns 988 shares of the company’s stock worth $94,000 after purchasing an additional 153 shares during the last quarter. Trust Co. of Oklahoma increased its stake in shares of Novartis by 2.9% during the 4th quarter. Trust Co. of Oklahoma now owns 14,425 shares of the company’s stock worth $1,366,000 after purchasing an additional 406 shares during the last quarter. Welch Group LLC increased its stake in shares of Novartis by 1.0% during the 4th quarter. Welch Group LLC now owns 327,478 shares of the company’s stock worth $31,009,000 after purchasing an additional 3,118 shares during the last quarter. Fulton Bank N.A. increased its stake in shares of Novartis by 9.3% during the 4th quarter. Fulton Bank N.A. now owns 3,186 shares of the company’s stock worth $302,000 after purchasing an additional 270 shares during the last quarter. Finally, Watch Point Trust Co increased its stake in shares of Novartis by 0.3% during the 4th quarter. Watch Point Trust Co now owns 42,657 shares of the company’s stock worth $4,039,000 after purchasing an additional 115 shares during the last quarter. Hedge funds and other institutional investors own 10.61% of the company’s stock.

NVS has been the subject of several research analyst reports. ValuEngine upgraded shares of Novartis from a “sell” rating to a “hold” rating in a research note on Saturday, October 19th. Cowen restated a “buy” rating and set a $100.00 price target on shares of Novartis in a research note on Friday, October 25th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. Novartis currently has a consensus rating of “Hold” and an average price target of $93.34.

Novartis stock traded down $0.64 during mid-day trading on Monday, reaching $93.24. The company’s stock had a trading volume of 139,062 shares, compared to its average volume of 1,543,317. Novartis AG has a 12-month low of $74.70 and a 12-month high of $96.06. The company has a market capitalization of $215.13 billion, a P/E ratio of 18.39, a PEG ratio of 1.94 and a beta of 0.59. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.73 and a current ratio of 0.95. The firm’s fifty day moving average price is $94.28 and its two-hundred day moving average price is $90.42.

Novartis Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Recommended Story: How prevalent are 12b-1 fees?

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.